- Home
- NBY vs ATHA Comparison
NBY vs ATHA Comparison
Compare NBY & ATHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBY
- ATHA
- Stock Information
- Founded
- NBY 2000
- ATHA 2011
- Country
- NBY United States
- ATHA United States
- Employees
- NBY N/A
- ATHA N/A
- Industry
- NBY
- ATHA Medicinal Chemicals and Botanical Products
- Sector
- NBY
- ATHA Health Care
- Exchange
- NBY Nasdaq
- ATHA Nasdaq
- Market Cap
- NBY 15.7M
- ATHA 14.8M
- IPO Year
- NBY 2007
- ATHA 2020
- Fundamental
- Price
- NBY $1.20
- ATHA N/A
- Analyst Decision
- NBY Strong Buy
- ATHA
- Analyst Count
- NBY 1
- ATHA 0
- Target Price
- NBY $0.85
- ATHA N/A
- AVG Volume (30 Days)
- NBY 1.2M
- ATHA 47.2K
- Earning Date
- NBY 11-06-2025
- ATHA 11-06-2025
- Dividend Yield
- NBY N/A
- ATHA N/A
- EPS Growth
- NBY N/A
- ATHA N/A
- EPS
- NBY 0.41
- ATHA N/A
- Revenue
- NBY $9,781,000.00
- ATHA N/A
- Revenue This Year
- NBY $23.91
- ATHA N/A
- Revenue Next Year
- NBY $32.05
- ATHA N/A
- P/E Ratio
- NBY $3.52
- ATHA N/A
- Revenue Growth
- NBY 113.47
- ATHA N/A
- 52 Week Low
- NBY $0.46
- ATHA $2.20
- 52 Week High
- NBY $4.44
- ATHA $8.26
- Technical
- Relative Strength Index (RSI)
- NBY 40.93
- ATHA 61.27
- Support Level
- NBY $1.22
- ATHA $4.03
- Resistance Level
- NBY $1.64
- ATHA $4.25
- Average True Range (ATR)
- NBY 0.24
- ATHA 0.28
- MACD
- NBY -0.16
- ATHA 0.04
- Stochastic Oscillator
- NBY 0.38
- ATHA 70.43
About NBY NovaBay Pharmaceuticals Inc.
NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically-proven eyecare, wound care, and skin care products. Its product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratory tested to have broad antimicrobial properties as it removes foreign material, including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available directly to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease.
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.